Rituximab in the treatment of refractory pulmonary sarcoidosis
Nadera J. Sweiss, Elyse E. Lower, Mehdi Mirsaeidi, Steven Dudek, Joe G.N. Garcia, David Perkins, Patricia W. Finn, Robert P. Baughman
European Respiratory Journal 2014; DOI: 10.1183/09031936.00224513
Nadera J. Sweiss
1University of Illinois Hospital and Health Sciences System, Chicago, IL,
Elyse E. Lower
2University of Cincinnati Medical Center, Cincinnati, OH,
Mehdi Mirsaeidi
3Division of Pulmonary and Critical Care, University of Illinois, Chicago, IL,
Steven Dudek
3Division of Pulmonary and Critical Care, University of Illinois, Chicago, IL,
Joe G.N. Garcia
4University of Arizona, Tucson, AZ,
David Perkins
5Dept of Surgery, University of Illinois, Chicago, IL,
Patricia W. Finn
3Division of Pulmonary and Critical Care, University of Illinois, Chicago, IL,
Robert P. Baughman
6University of Cincinnati Medical Center, Interstitial Lung Disease and Sarcoidosis Clinic Dept of Internal Medicine, Cincinnati, OH, USA
Abstract
Rituximab may be considered as third-line therapy for refractory pulmonary sarcoidosis http://ow.ly/sLmtD
- Received November 5, 2013.
- Accepted January 10, 2014.
- © ERS
Vol 63 Issue 4
Table of Contents
Rituximab in the treatment of refractory pulmonary sarcoidosis
Nadera J. Sweiss, Elyse E. Lower, Mehdi Mirsaeidi, Steven Dudek, Joe G.N. Garcia, David Perkins, Patricia W. Finn, Robert P. Baughman
European Respiratory Journal Jan 2014, erj02245-2013; DOI: 10.1183/09031936.00224513